2022
Pathogenesis to management of hepatocellular carcinoma
Da B, Suchman K, Lau L, Rabiee A, He A, Shetty K, Yu H, Wong L, Amdur R, Crawford J, Fox S, Grimaldi G, Shah P, Weinstein J, Bernstein D, Satapathy S, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes & Cancer 2022, 13: 72-87. PMID: 36533190, PMCID: PMC9746873, DOI: 10.18632/genesandcancer.226.Peer-Reviewed Original ResearchHepatocellular carcinomaCommon primary liver cancerEarly-stage hepatocellular carcinomaLiver-directed therapiesPathogenesis of HCCPrimary liver cancerMetastatic hepatocellular carcinomaViable animal modelAdvanced diseaseLiver resectionSystemic therapyPoor prognosisRisk factorsHCC managementHistological classificationLiver cancerNew therapiesAnimal modelsTherapyTissue samplingRelevant biomarkersAlcohol useMolecular targetsCarcinomaPathogenesis
2013
Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers
Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers. PLOS ONE 2013, 8: e81408. PMID: 24282590, PMCID: PMC3839880, DOI: 10.1371/journal.pone.0081408.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaOverall survivalFemale patientsMiR-195MiR-122Survival outcomesPlasma levelsEGFR statusNon-smoking female patientsCox proportional hazards regressionKaplan-Meier survival analysisEGFR-mutant patientsProportional hazards regressionAdvanced disease stageEGFR mutation statusTime-dependent receiverMiR-122 expressionReal-time RT-PCRHazards regressionPoor prognosisPrognostic valueDisease stageNon smokersMutant patientsEGFR mutations
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients
2007
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
Smith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.Peer-Reviewed Original ResearchConceptsExcision repair cross-complementation group 1High ERCC1 expressionOvarian cancer patientsERCC1 expressionC genotypeDisease progressionGreater riskCancer patientsTreatment responseCodon 118Postoperative platinum-based chemotherapyEpithelial ovarian cancer patientsLow ERCC1 expressionSurvival of patientsPlatinum-based chemotherapyEpithelial ovarian cancerERCC1 mRNA expressionCombination of platinumERCC1 genotypePlatinum chemotherapyPoor prognosisOvarian cancerPaclitaxel treatmentGroup 1T genotype